An experimental treatment happens to be the solution to delay Alzheimer's symptoms in some people. These people are the ones who are genetically destined to get the disease in their 40s or 50s. These new findings form ongoing research has now been caught up in Trump administration funding delas. The early results of the study has been published on Wednesday and the participants too are worried that politics could cut their access to a possible lifeline.

One of the participants had said, "It is still a study but it has given me an extension to my life that I never banked on having." The participant is named Jake Henrichs, form New York City, who is 50 years old. He is one of them to be treated in that study for more than a decade now and has remained symptom-free despite inheriting an Alzheimer's-causing gene that had killed his father and brother around the same age.

Slowing Down The Symptoms

Two drugs which can modestly slow down early-stage Alzheimer's are sold in the United States. These drugs clear the brain of one of its hallmarks, a sticky gunk-like part called the amyloid. However, there have not been any hints that removing amyloid far earlier, way many years before the first symptoms appear, may postpone the disease.

How Was The Research Conducted?

The research is led by Washington University in St Louis, which involved families that passed down rare gene mutation as participants. This meant it was almost guaranteed that they will develop symptoms at the same age their affected relatives did.

The new findings is based on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight years. Long-term amyloid removal cut in half their risk of symptom onset. The study is published in the journal Lancet Neurology.

Washington University's Dr Randall Bateman, who directs the Dominantly Inherited Alzheimer's Network of studies involving families with these rare genes says, "What we want to determine over the next five years is how strong is the protection. Will they ever get the symptoms of Alzheimer’s disease if we keep treating them?”

The researchers before though did not know what exactly caused Alzheimer's which affects nearly 7 million Americans, most of them in their later life. However, it is clear that these silent changes occur in the brain at least two decades before the first symptom shows up. The big contributor. At some point amyloid buildup can trigger a protein named tau that then starts to kill neurons, which can lead to cognitive decline.

Researchers are now thus studying the Tau-fighting drugs and are looking into other factors, like inflammation, brain's immune cells and certain virus.

The National Institute of Health (NIH) has expanded its focus as researchers have found more reasons for Alzheimer's. In 2013, the NIH's National Institute on Aging funded 14 trials of possible Alzheimer's drugs over a third targeting amyloid. By last fall, there were 68 drugs and 18% of them target amyloid. However, there are scientists too who think that amyloid is not everything and their is way more in the brain tissue, immune cells, and more which can be studied.

A total of 52,10,302 girls across India have received the Human Papillomavirus (HPV) vaccine under the nationwide campaign launched by Prime Minister Narendra Modi in February, the government informed Parliament during the ongoing Monsoon Session.

The nationwide vaccination campaign for 14-year-old girls was launched from Rajasthan's Ajmer as part of India's efforts to eliminate cervical cancer.

“The nationwide HPV vaccination campaign was launched on February 28, for approximately 1.2 crore eligible beneficiary girls aged 14 years across all 36 States and Union Territories. As of July 15, a total of 52,10,302 girls have received the HPV vaccine across the country,” Union Minister of State for Health and Family Welfare Anupriya Patel said in a written reply in the Rajya Sabha.

Free HPV Vaccination

Read More: Fact Check: Common Myths Around HPV Vaccine And How It Will Prevent Cervical Cancer

The Minister said the HPV vaccine is being provided free of cost at designated government health facilities, including:

• Ayushman Arogya Mandirs–Primary Health Centers (PHCs)

• Community Health Centers (CHCs)

• Sub-District Hospitals (SDHs) and District Hospitals (DHs)

• Government Medical Colleges (GMCs)

She also said the government's cervical cancer prevention strategy includes HPV vaccination, screening, early diagnosis at Ayushman Arogya Mandirs (AAMs), and treatment through Day Care Cancer Centers (DCCCs).

Immunization Coverage Remains Above 90%

The Minister also updated Parliament on India's immunization program.

“As per the National Health Policy 2017 goals, the National Full Immunization Coverage has been maintained more than 90% for the last four years,” Patel said. National full immunization coverage was:

• 94.7% in 2022–23

• 93.7% in 2023–24

• 98.3% in 2024–25

• 97.9% in 2025–26

Strengthening Pandemic Preparedness

Also read: Healthcare In India No Longer A Privilege, Becoming A Right: PM Modi

Patel also said that the government has taken several steps to improve preparedness for future pandemics and public health emergencies, including:

• Launch of the Pradhan Mantri-Ayushman Bharat Health Infrastructure Mission (PM-ABHIM) to strengthen public health infrastructure, disease surveillance, diagnostics, research, and emergency response.

• Strengthening the Integrated Disease Surveillance Program (IDSP) with trained multidisciplinary Rapid Response Teams (RRTs).

• Expansion of the Indian Council of Medical Research's Virus Research and Diagnostic Laboratory (VRDL) network to more than 160 laboratories for pathogen diagnosis.

Meanwhile, the Nationwide Viral Research and Diagnostic Laboratories (VRDL) network under ICMR has been expanded to 163 laboratories, comprising 11 Regional VRDLs, 27 State VRDLs and 125 Medical College VRDLs, to strengthen diagnostic capacity across the country.

Cervical Cancer Cases Decline

Read to Know: SHetA2: India's Indigenous Drug Candidate For Cervical Cancer

Meanwhile, recent data from the ICMR's National Cancer Registry Program (NCRP) show that India has recorded a significant decline in its cervical cancer burden.

According to the latest estimates, new cervical cancer cases have fallen by 37% over the past decade, declining from about 1.27 lakh cases annually to around 79,000, marking a major public health milestone in the fight against one of the country's most common cancers among women.

Unlike many other cancers, cervical cancer is considered highly preventable through HPV vaccination, regular screening, and timely treatment of precancerous lesions.

The WHO global targets for 2030 include vaccinating 90 percent of girls by age 15, screening 70 percent of women by ages 35 and 45, and ensuring 90 percent of women with pre-cancer and invasive cancer receive appropriate treatment.

Researchers at the Indian Institute of Technology (IIT) Kanpur have uncovered how an experimental vaccine booster molecule activates the body's immune system, a breakthrough that could help researchers develop safer and more effective vaccines in the future.

The study, published this month in the Proceedings of the National Academy of Sciences (PNAS), provides the first detailed structural view of how a synthetic molecule called EP67 binds to and activates an important immune receptor known as C5aR1. The findings offer researchers a molecular blueprint for improving vaccine adjuvants, the ingredients added to vaccines to strengthen and prolong immune protection.

Unlike vaccines, which train the immune system to recognize a specific pathogen, adjuvants help amplify the body's immune response, making vaccines more effective.

Inspired By The Body's Natural Immune System

Also read: US Reports 2,260 Measles Cases In Just Over Six Months Of 2026: CDC

The researchers developed EP67 by taking inspiration from C5a, a naturally occurring immune protein released during bacterial and viral infections. While C5a helps activate immune cells to fight infections, prolonged activation can trigger harmful inflammation and damage healthy tissues.

To overcome this challenge, the IIT Kanpur team engineered EP67, a much smaller version consisting of just 10 amino acids.

The molecule retains the beneficial immune-stimulating properties of C5a while limiting the inflammatory effects. According to the researchers, EP67 selectively activates dendritic cells and macrophages, two immune cells that play a central role in generating long-lasting immunity, while largely avoiding activation of neutrophils, immune cells that are often responsible for excessive inflammatory responses.

This selective activation makes EP67 a promising candidate as a vaccine adjuvant capable of producing stronger immune protection without triggering inflammation.

Earlier Studies

Previous animal studies have shown the potential of EP67 in boosting vaccine responses.

When incorporated into experimental vaccines against multiple viruses, including SARS-CoV-2, the virus responsible for COVID-19, mice developed stronger immune responses than those receiving vaccines alone. Researchers also observed faster recovery in infected animals.

Beyond vaccines, EP67 has also shown promise against bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA), a major antibiotic-resistant pathogen.

However, the molecule has not yet entered clinical use in humans, and additional preclinical research will be required before human trials can begin.

Although scientists had previously observed EP67's immune-boosting effects, precisely how the molecule worked remained vague for a long time.

The IIT Kanpur researchers found that EP67 binds to C5aR1, a receptor located on the surface of immune cells. C5aR1 belongs to the large family of G protein-coupled receptors (GPCRs), which are involved in transmitting signals into cells and are among the most common targets for modern medicines.

Using cryo-electron microscopy (cryo-EM), the team captured near-atomic-resolution images showing EP67 adopting a hook-like shape that fits into the centre of the receptor, switching it on and initiating immune activation.

The structural insights have already enabled researchers to redesign EP67 by modifying its amino acid sequence to improve its stability and receptor binding. The next steps would be refining the formulation and introducing it in pre-clinical tests.

People living with Type 2 diabetes may be significantly more vulnerable to severe, potentially life-threatening complications from dengue, according to a new review by diabetes specialists.

The paper, presented in July 2026 and slated for publication in the International Journal of Diabetes & Technology (IJDT), also recommends combining dengue vaccination into routine diabetes care in dengue-endemic regions to better protect patients who are at high risk.

The review comes as many countries, including India, continue to witness surges in dengue cases during the monsoon months.

Can Type 2 Diabetes Make Dengue More Severe?

Also read: Will Waterborne Diseases Rise In The Future? New Study Says Climate Change Could Be A Major Driver

According to the researchers, chronic high blood sugar weakens the immune system and damages blood vessels, making it harder for the body to fight dengue infection.

It increases the risk of vascular leakage, severe bleeding, organ damage, and other complications associated with severe dengue.

The review notes that diabetes contributes to chronic inflammation, endothelial dysfunction, and impaired immune responses, all of which may worsen the course of dengue infection.

The researchers argue that dengue prevention should become part of routine diabetes management in countries where dengue is endemic. Lead author Dr. Jothydev Kesavadev, diabetologist, said, "People with Type 2 diabetes represent a particularly vulnerable group during dengue outbreaks.

Preventive strategies, including vaccination where appropriate, should become an integral part of diabetes care to reduce severe illness and deaths."

The review was co-authored by several diabetes specialists from across India, including Dr. Niti Pall, President-Elect of the International Diabetes Federation Europe.

It was presented during the 14th Jothydev's Professional Education Forum Annual Global Diabetes Convention in Kovalam, Kerala, and its publication was formally released by Kerala Health Minister K. Muraleedharan.

Earlier Research

Also read: DengiAll, India's First Dengue Vaccine Clears Phase III Trials, May Soon Enter Markets

While the current paper is a review rather than a new clinical trial, it is supported by a growing body of evidence. A 2024 review published in Health Science Reports found that diabetes is significantly associated with severe dengue, death, elevated liver enzymes, and thrombocytopenia.

Similarly, a 2025 review in the International Health journal concluded that accumulating evidence increasingly supports diabetes as an important comorbidity contributing to poor dengue outcomes.

Should People With Diabetes Receive The Recently Approved Dengue Vaccine?

Also read: India’s First Approved Dengue Vaccine: Takeda’s QDENGA Protects Against All Four Virus Serotypes

The findings come as India recently approved its first dengue vaccine, QDENGA (TAK-003). The vaccination should follow national guidelines and individual medical advice. Experts emphasize that vaccination complements, rather than replaces, mosquito bite prevention measures.

QDENGA (TAK-003) is a live-attenuated tetravalent dengue vaccine designed to protect against all four dengue virus serotypes.

It is administered as two 0.5 mL subcutaneous doses, given three months apart.

The vaccine is built on a DENV-2 backbone, incorporating structural proteins from DENV-1, DENV-3 and DENV-4 to provide broad immune protection.

The World Health Organization (WHO) recommends QDENGA for use in dengue-endemic settings without the need for pre-vaccination screening. The vaccine is also included in the WHO List of Prequalified Vaccines, allowing procurement through agencies such as UNICEF and PAHO.

Precautions

Experts recommend that people with diabetes:

• Maintain good blood sugar control.
• Avoid mosquito bites by using repellents, long-sleeved clothing, and eliminating stagnant water around homes.
• Seek medical attention immediately if dengue symptoms such as high fever, severe headache, vomiting, abdominal pain, bleeding, or rash develop.
• Discuss dengue vaccination with their healthcare provider if they live in an endemic region and are eligible under national recommendations.